🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  3. Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  5. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Paclitaxel eluting PTCA balloon

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary In-stent Restenosis

    phase 3 other active

    1 trial

  7. Paclitaxel or docetaxel + Cisplatin or carboplatin

    The First People's Hospital of Lianyungang

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  8. Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  9. Paclitaxel-releasing PTA balloon catheter

    Lxo Ireland Designated Activity Company

    Arteriovenous Fistula Renal Dialysis Devices Obstruction

    phase 3 other completed

    1 trial

  10. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  11. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Lacuna Pharma Pty Ltd

    Acute pain

    phase 3 small molecule active

    1 trial

  12. Parathyroid Hormone (PTH)

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  13. Parathyroid hormone

    Takeda

    Disruption or Dehiscence of Closure of Sternum or Sternotomy

    phase 3 small molecule completed

    1 trial

  14. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Biotech Pharmaceutical Co.,

    Influenza

    phase 3 mab active

    1 trial

  15. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  16. Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  17. Peer Mentoring Intervention for HCV-Infected IDUs

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    phase 3 other completed

    1 trial

  18. Peg interferon alpha-2b

    Universal Integrated

    Hepatitis C

    phase 3 small molecule terminated

    1 trial

  19. PegIntron (peginterferon alfa-2b)

    Universal Integrated

    Hepatitis C, Chronic

    phase 3 mab terminated

    1 trial

  20. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial

  21. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  22. Pegylated Interferon Alfa-2a

    Hoffmann-La Roche

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  23. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  24. Pembrolizumab

    Incyte

    Renal Cell Carcinoma (RCC)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources